Organon & Co. (OGN) Price Prediction 2026–2050

Organon & Co. develops and delivers women’s health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.

Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss.

The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co. (OGN) is a healthcare company focused on women’s health and related therapies, with a broad product portfolio across prescription brands and medical devices. Its current price sits at $13.43 per share and the company carries a market capitalization of $3.53B, ranking 1635 by market size.

The stock’s price outlook is informed by a multi-year forecast that envisions a rise in the average price from 2026 onward, with substantial upside projected into the 2030s and beyond. The forecast shows a wide range between yearly minimums and maximums, reflecting volatility but an overall bullish trajectory over the long term.

Forecasts extend well into the next several years, with the 2026 average price at $13.43 and a 2026 range of $5.70 to $17.18. By 2027, the average is forecast at $15.20 (range $12.43–$19.43) with a 13.2 ROI and neutral sentiment. The 2028–2035 path shows continued upside, reaching a 2030 average of $21.81 (range $17.03–$29.76) and 62.4 ROI with bullish sentiment; 2031–2035 extend the climb to an average of $24.66, $28.18, $29.93, and $32.90 respectively, all with bullish sentiment.

In the long horizon, 2040 is forecast at an average of $51.24 (range $36.37–$78.19) with 281.5 ROI, and 2050 at an average of $93.03 (range $61.58–$152.16) with 592.7 ROI. These figures point to a strong long-term uptrend, but they are estimates and not guarantees. Investors should consider the possibility of volatility and downside risk, even as the outlook trends positive across multiple years.